If medicine had a godfather of evidence, his name would be Archie. Archibald Leman Cochrane, that is.
Cochrane wasn’t just a physician—he was a rebel against tradition. In the 1970s, he looked around at the medical world and said, essentially: “Too much of what we do is based on habit and authority, not actual proof.”
He proposed a radical idea: let’s rank evidence by reliability. At the bottom sat case reports and expert opinions—interesting, but hardly solid. Above that came observational studies, then randomized controlled trials (RCTs). And sitting proudly at the top of the pyramid? Systematic literature reviews (SLRs): structured evaluations that capture all the studies, critique their quality, and synthesize their findings.
That hierarchy became the foundation of what we now call Evidence-Based Medicine (EBM).
Why Systematic Reviews Matter
Systematic reviews aren’t academic busywork. They’re the reason guidelines from the World Health Organization, NICE, and the American Society of Clinical Oncology (ASCO) are trustworthy. They’re why the FDA demands comprehensive, systematic evidence before approving a therapy.
The principle is simple: no single trial tells the full story, but when you put the whole picture together—carefully, transparently, reproducibly—you can make decisions that change lives.
But Have We Forgotten Cochrane?
Fast forward to today. AI chatbots can answer clinical questions in seconds. They sound authoritative, but they don’t follow Cochrane’s hierarchy. They don’t systematically review literature. They don’t grade evidence for quality. And they definitely don’t show their work.
In oncology, where new studies are published daily, this is not a minor issue. A chatbot that casually cites one study—or worse, invents a citation—could mislead a physician into recommending something harmful, or missing a life-saving option.
It’s like we built the evidence pyramid over decades, and now, dazzled by shiny AI, we’re forgetting why we built it in the first place.
The Way Forward
The future of evidence isn’t abandoning systematic reviews. It’s making them living: constantly updated, rigorous, and transparent. AI does have a role to play here—not as a chatbot dispensing unverified answers, but as a tool that accelerates and augments systematic reviews.
That’s exactly what we’re building at Oncoscope: living SLRs, human-vetted and PhD-curated, augmented by AI. Reliable, current, and ready to support the most important decisions in oncology.
Because in cancer care, evidence isn’t an academic debate. It’s a matter of life, harm, or hope.
So the question is: are we going to let chatbots distract us from Cochrane’s lesson—or use AI to fulfill it?
Anna Forsythe is the Founder and President of Oncoscope-AI, the first platform to bring together real-time oncology treatment data, clinical guidelines, research publications, and regulatory approvals — all in one place, just like Expedia for cancer care. Available free to oncology professionals worldwide, Oncoscope-AI is redefining how cancer care information is accessed and applied.
A clinically trained Doctor of Pharmacy (PharmD), Anna also holds a Master’s in Health Economics and Policy from the University of Birmingham (UK) and an MBA from Columbia University. She previously co-founded Purple Squirrel Economics (acquired by Cytel in 2020) and led Global Value and Access at Eisai Pharmaceuticals, following earlier roles at Novartis and Bayer in clinical research and health economics.
